NCT03982030 is a Phase 4 clinical trial of Dalbavancin in Gram-Positive Bacterial Infections, sponsored by Wake Forest University Health Sciences.

Who is sponsoring NCT03982030?

NCT03982030 is sponsored by Wake Forest University Health Sciences.

What drugs are being tested in NCT03982030?

Interventions in NCT03982030: Dalbavancin.

What condition does NCT03982030 study?

NCT03982030 studies Gram-Positive Bacterial Infections, Soft Tissue Infections.

Is NCT03982030 still recruiting?

NCT03982030 is currently withdrawn. Last updated 1 May 2023.

Last reviewed 2023-05-01 · How we verify

NCT03982030

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-label, Pilot Clinical Trial of Dalbavancin for the Treatment of Susceptible Gram-positive Infections Requiring Prolonged Intravenous Antibiotic Therapy

Withdrawn Phase 4 Last updated 1 May 2023

What this trial tests

Phase 4 trial testing Dalbavancin in Gram-Positive Bacterial Infections. Withdrawn.

Timeline

1 April 2023

Primary endpoint
1 April 2025

1 July 2025

Quick facts

Lead sponsor	Wake Forest University Health Sciences
Phase	Phase 4
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 April 2023
Primary completion	1 April 2025
Estimated completion	1 July 2025

Drugs / interventions tested

Dalbavancin (DALBAVANCIN) — full drug profile →

Conditions studied

Gram-Positive Bacterial Infections — all drugs for Gram-Positive Bacterial Infections →
Soft Tissue Infections — all drugs for Soft Tissue Infections →

Sponsor

Wake Forest University Health Sciences

Who can join

18 and older, any sex, with Gram-Positive Bacterial Infections or Soft Tissue Infections. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of participants with resolution of infection
Time frame: Week 6
Number of participants with no recurrent signs or symptom of infection

Sponsor's own description

The purpose of this research is to determine if a new antibiotic called dalbavancin will work to treat and cure certain infections while reducing the need for daily antibiotics by vein.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms.
Koulenti D, Xu E, Mok IYS, Song A, et al · · 2019 · cited 31× · PMID 31426596 · DOI 10.3390/microorganisms7080270
New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.
Tran TT, Gomez Villegas S, Aitken SL, Butler-Wu SM, et al · · 2022 · cited 26× · PMID 35475634 · DOI 10.1128/aac.02614-20
Staph wars: the antibiotic pipeline strikes back.
Douglas EJA, Laabei M. · · 2023 · cited 10× · PMID 37656158 · DOI 10.1099/mic.0.001387

Verify or expand the search:

Other trials of Dalbavancin

Trials testing the same drug.

NCT05046860 — Efficacy of Dalbavancin in Osteoarticular Infections Associated With Hip and Knee Replacements · NA · unknown
NCT04959799 — Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections (DALBADIA) · completed
NCT04847921 — Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition · Phase 2, PHASE3 · terminated
NCT04775953 — DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia · Phase 2 · completed
NCT04624451 — Evaluation of Intravenous Dalbavancin for Peritonitis · terminated

Other recruiting trials for Gram-Positive Bacterial Infections

Currently open trials in the same condition.

NCT06592586 — A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women · Phase 2, PHASE3 · active not recruiting

Other Wake Forest University Health Sciences trials

Trials by the same sponsor.

NCT07474090 — Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial · NA · not yet recruiting
NCT07282444 — A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial · NA · not yet recruiting
NCT06876896 — Intra-abdominal Pressure (IAP) During PFA Treatment of A-fib/ A-Flutter · NA · recruiting
NCT07227051 — Optimizing Self-Monitoring Feedback Delivery for the Treatment of Overweight and Obesity · NA · recruiting
NCT07215624 — Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03982030 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wake Forest University Health Sciences
Last refreshed: 1 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03982030.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing